Merkel cell carcinoma is a rare, highly aggressive skin cancer. With multimodal treatment including chemo- and immunotherapy, the 5-y overall survival ranges from 14% to 62%, depending on the disease stage at diagnosis (1). New treatment options are therefore urgently needed. Given the overexpression of somatostatin receptors (SSTRs) due to its neuroendocrine features, SSTR-directed therapy could be a promising target in metastatic Merkel cell carcinoma (2–4).
To further investigate this potential, 2 clinical trials are already ongoing in which peptide receptor radionuclide therapy with SSTR agonists are being studied in combination with immunotherapy (GoTHAM trial, NCT04261855; iPRRT trial, NCT05583708).
Although various agonistic SSTR-targeting tracers have been established for years in metastatic Merkel cell carcinoma and other neuroendocrine tumor entities, tracers with antagonistic receptor interaction are recognized as a new, promising theranostic option, as they can achieve high tumor uptake and prolonged retention as compared with agonists (5).
We report the case of a 77-y-old man with recurrent metastatic Merkel cell carcinoma who underwent PET/CT with the 68Ga-labeled SSTR antagonist SSO120 (international nonproprietary name: satoreotide trizoxetan; also known as NODAGA-JR11, OPS202, and IPN01070; injected dose, 160 MBq; scan acquisition, 60 min after injection) (6,7) to explore the possibility for peptide receptor radionuclide therapy (Fig. 1A). Informed consent was obtained from the patient. Compared with [18F]FDG PET (Fig. 1B), a more intense tracer uptake and excellent tumor-to-background ratios were observed using [68Ga]Ga-SSO120 PET, for example, in a pelvic (right iliac) lymph node metastasis with an SUVmax of 11.6 versus 5.5 on [18F]FDG PET. The average SUVmax in the 6 measurable tumor lesions was 13.4 ± 5.0 with [68Ga]Ga-SSO120 versus 9.5 ± 4.2 with [18F]FDG PET. Given the still-localized tumor stage, the patient underwent surgery. High membranous SSTR expression on all tumor cells was confirmed by immunohistochemistry (score 3+; Fig. 1C).
FIGURE 1.
Maximum-intensity projections and axial sections of [68Ga]Ga-SSO120 (A) and [18F]FDG (B) PET/CT. Location of exemplary pelvic (right iliac) lymph node metastasis with SUVmax of 11.6 vs. 5.5 on [18F]FDG PET is indicated by white and black arrows, respectively. Intensity scale bars are SUV. Immunohistochemistry showed high membranous SSTR expression on all tumor cells (score 3+; C).
In conclusion, PET/CT with SSTR antagonists could serve as a noninvasive read-out for tumor biology and allow selection of candidates for SSTR-directed peptide receptor radionuclide therapy. Further research, especially regarding advantages over agonistic vectors, is highly warranted.
DISCLOSURE
No potential conflict of interest relevant to this article was reported.
REFERENCES
- 1. Becker JC, Stang A, DeCaprio JA, et al. Merkel cell carcinoma. Nat Rev Dis Primers. 2017;3:17077. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Buder K, Lapa C, Kreissl MC, et al. Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging. BMC Cancer. 2014;14:268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Meier G, Waldherr C, Herrmann R, Maecke H, Mueller-Brand J, Pless M. Successful targeted radiotherapy with 90Y-DOTATOC in a patient with Merkel cell carcinoma. Oncology. 2004;66:160–163. [DOI] [PubMed] [Google Scholar]
- 4. Askari E, Moghadam SZ, Wild D, et al. Peptide receptor radionuclide therapy in Merkel cell carcinoma: a comprehensive review. J Nucl Med Technol. 2023;51:22–25. [DOI] [PubMed] [Google Scholar]
- 5. Fani M, Mansi R, Nicolas GP, Wild D. Radiolabeled somatostatin analogs: a continuously evolving class of radiopharmaceuticals. Cancers (Basel). 2022;14:1172. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Zhu W, Cheng Y, Wang X, et al. Head-to-head comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study. J Nucl Med. 2020;61:897–903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Nicolas GP, Schreiter N, Kaul F, et al. Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J Nucl Med. 2018;59:915–921. [DOI] [PubMed] [Google Scholar]